Know Cancer

forgot password

Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Phase 2
21 Years
Open (Enrolling)
Thyroid Cancer

Thank you

Trial Information

Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Inclusion Criteria:

- Patients must have histopathologically confirmed at MSKCC thyroid carcinoma of
follicular cell origin (D-TC-FCO), which includes papillary, follicular, Hürthle
cell histology, or anaplastic along with their respective variants.

- Available pathology for RAF mutational testing (e.g., paraffin block or 5-10
unstained slides). It is not required that mutational testing be completed before
starting the clinical study.

- Patients must have surgically inoperable and/or recurrent/metastatic disease.

- Patients must have a PET scan prior to the protocol start date and have at least one
FDGavid lesion that has not been removed surgically or radiated (unless it has
progressed by RECIST criteria after the completion of radiation therapy and is still
FDG-avid). FDGavidity will be defined as any focus of increased FDG uptake greater
than normal activity with SUV maximum levels greater than or equal to 3. PET scan can
have been done at any time prior to the start of therapy, although it is recommended
that it be done within 3 months prior to the start of therapy.

- Patients must have measurable disease by RECIST criteria, defined as at least one
lesion that can be accurately measured in at least one dimension (longest diameter to
be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT
scan; performed ≤ 4 weeks of protocol start date.

- Patients must have progressive disease defined by at least one of the following
occurring during or after previous treatment (including RAI treatment):

The presence of new or progressive lesions on CT/MRI.

- New lesions on bone scan or PET scan.

- Rising thyroglobulin level (documented by a minimum of three consecutive rises, with
an interval of > 1 week between each determination).

Prior RAI therapy is allowed if > 3 months prior to initiation of therapy on this protocol
and evidence of progression (as defined above) has been documented in the interim. A
diagnostic study using <10 mCi of RAI is not considered RAI therapy.

- Patients may have received prior external beam radiation therapy to index lesions ≥ 4
weeks prior to initiation of therapy on this protocol if there has been documented
progression by RECIST criteria. Prior external beam radiation therapy to the
non-index lesions is allowed if ≥ 4 weeks prior to initiation of therapy on this

- ECOG performance status ≤ 2 (or Karnofsky performance status ≥ 60%).

- Patients must have normal organ and marrow function as defined below:

- Absolute neutrophil count ≥1,500/mcL

- Platelets ≥100,000/mcL

- Total bilirubin ≤ 1.5 X institutional ULN

- AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN

- Creatinine ≤ 1.5 X institutional ULN OR

- Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above
1.5 X institutional ULN [in this circumstance, either of a measured level based on a
24 hour urine collection, or a calculated level using the Cockcroft and Gault
equation: (140 - age in years) X (weight in kg) X (0.85 if female)/72 X serum Cr may
be used].

- International normalized ratio (INR) ≤ 1.5 (or in range INR, usually between 2 and 3,
if patient is on a stable dose of therapeutic warfarin).

- *ULN = upper limit of normal

- **unless liver metastasis present in which AST/ALT should be < 5 x ULN.

- Ability to understand and the willingness to sign a written informed consent

- Age 21 years old or older.

Exclusion Criteria:

- Patients may not be receiving any other investigational agents.

- Patients with known history of active intraparenchymal brain metastasis within
previous 3 months.

- Serious or non-healing wound, ulcer, or bone fracture.

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 28 days of treatment.

- Patients with a reported history of clinically active diverticulosis or
diverticulitis in the prior 3 years.

- Patients with clinically significant cardiovascular disease as defined by the

History of CVA within past 6 months

- Myocardial infarction, CABG or unstable angina within past 6 months

- New York Heart Association grade III or greater congestive heart failure or Canadian
Cardiovascular Class grade III or greater angina within past 6 months (Appendices
B&C) Clinically significant peripheral vascular disease within past 6 months

- Pulmonary embolism, DVT, or other thromboembolic event within past 6 months

- Uncontrolled coronary artery disease, angina, congestive heart failure, or
ventricular arrhythmia requiring acute medical management within past 6 months

- History of myocardial infarct, cerebrovascular accident, or transient ischemic event
within the past 6 month

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements.

- While the use of Angiotensin-Converting Enzyme (ACE) inhibitors is not absolutely
excluded, efforts should be made to see if patients on ACE inhibitors can be taken
off the medication or switched to another medication.

- Pregnant women will be ineligible; breastfeeding should be discontinued if the mother
is treated with study drugs.

- The use of agents that inhibit or induce CYP3A metabolism is not strictly prohibited,
but should be avoided if possible. Potential CYP3A inducing agents include
carbamazepine, phenytoin, barbiturates, rifabutin, rifampicin, and St. John's Wort.
Potential CYP3A inhibitors include protease inhibitors, antifungals, macrolide
antibiotics, nefazodone, and selective serotonin inhibitors.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine the objective response rate of the combination sorafenib and temsirolimus in I-131 refractory thyroid cancer.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Eric Sherman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

December 2009

Completion Date:

December 2013

Related Keywords:

  • Thyroid Cancer
  • thyroid
  • follicular cell
  • papillary cell
  • Hurthle cell
  • BAY 43-9006
  • Temsirolimus
  • Sorafenib
  • 09-148
  • Thyroid Neoplasms
  • Thyroid Diseases



Memorial Sloan Kettering Cancer Center New York, New York  10021
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center Sleepy Hollow, New York  10591
Memorial Sloan-Kettering at Basking Ridge Basking Ridge, New Jersey  07920
Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York  11725
Memorial Sloan-Kettering at Mercy Medical Center Rockville Centre, New York